Linkedin Youtube
Launch Digital Edition

Webinars and Commercial Conversations — Register Now

Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.

Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace Directory

Court rules in favor of Qiagen in patent dispute

March 2025—Qiagen announced that the German Federal Patent Court has ruled in Qiagen’s favor in a patent dispute against SD Biosensor. The court’s decision upholds Qiagen’s intellectual property rights involving the German part of European patent EP 3 421 997, which protects key innovations in tuberculosis detection. Patents covering these innovations have been issued to Qiagen in several other countries, the company said in a press statement, and form part of a group of more than 120 patents currently issued for QuantiFeron.

Leica Biosystems launches HistoCore Chromax WS

March 2025—Leica Biosystems announced the next iteration in its staining and coverslipping portfolio, the HistoCore Chromax Workstation. The HistoCore Chromax WS includes a reagent management system and features graphical, touchscreen interfaces. It is for in vitro diagnostic use and available in select countries.

Illumina unveils spatial transcriptomics technology

March 2025—Illumina announced a new spatial technology program that the company says will empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale. Enabled on Illumina sequencers and a new multimodal analysis platform, Illumina Connected Multiomics, the spatial technology delivers unbiased whole-transcriptome profiling with cellular resolution and high sensitivity. The technology will allow researchers to examine the spatial proximity of millions of cells per experiment, enabled by a capture area nine times larger than existing technologies and with four times greater resolution. It is compatible with Illumina NextSeq and NovaSeq sequencers.

FDA clears BioFire FilmArray GI Panel Mid

March 2025—BioMérieux announced that its BioFire FilmArray Gastrointestinal (GI) Panel Mid has obtained FDA clearance. The molecular PCR test is capable of simultaneously detecting 11 pathogens directly from a stool sample from individuals presenting with signs or symptoms of gastrointestinal infection. It runs on the BioFire FilmArray 2.0 and Torch PCR platforms, requires about two minutes of hands-on time, and has an approximate run time of one hour. The panel will be commercially available in the United States at the

Roche unveils sequencing by expansion technology

March 2025—Roche unveiled a proprietary sequencing by expansion (SBX) technology that offers ultra-rapid, high-throughput sequencing that is flexible and scalable for a broad range of applications, including whole genome sequencing, whole exome sequencing, and RNA sequencing. The novel sequencing approach uses a sophisticated biochemical process to encode the sequence of a target nucleic acid molecule (DNA or RNA) into a measurable surrogate polymer called an Xpandomer.

Cision Vision introduces InVision, Vision Board

March 2025—Cision Vision has introduced its In­Vision imaging system and Vision Board. The technologies aim to enhance the efficiency and accuracy of lymph node dissections at the gross bench.

FDA clears Thermo Fisher SARS-CoV-2, flu A/B, RSV test

March 2025—Thermo Fisher Scientific has received FDA 510(k) clearance for the Applied Biosystems TaqPath COVID-19, Flu A, Flu B, RSV Select Panel. The real-time PCR-based multiplex test covers the detection and differentiation of SARS-CoV-2, influenza A and B, and respiratory syncytial virus and enables the detection of co-infection. The panel runs on the Applied Biosystems QuantStudio 5 Dx real-time PCR system.

Q-linea nabs second contract in U.S. for ASTar instrument

March 2025—Q-linea announced that it has signed a second commercial contract for its ASTar instrumentation in the United States. Installation and training in a multihospital system will take place by the end of the first quarter this year. The quantitative antimicrobial susceptibility test system uses high-speed, time-lapse microscopy imaging of organisms in positive blood culture samples to determine the minimum inhibitory concentration of specific antimicrobial-organism combinations.

Labcorp test for advanced solid tumors now for clinical use

March 2025—Labcorp announced that its Labcorp Plasma Complete is now available for clinical use. The assay is a ctDNA-based comprehensive genomic profiling solution for patients with advanced solid tumors. It detects genomic alterations in circulating tumor DNA across 521 genes and covers established and emerging biomarkers associated with FDA-approved therapies, guideline-driven treatments, and clinical trial eligibility.

MARKETPLACE

TRENDING